Publications
Selected Research Articles
Wang Y, Meraz IM, Qudratullah M, Kotagiri S, Han Y, Xi Y, Wang J, Akdemir KC, Roth JA, Lissanu Y. Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy. Cancer Res, 2025. e-Pub 2025. PMID: .
Lawson NM, Ye L, Cho CY, Zhao B, Mitchell T, Martin-Barrio I, Beernaert B, Gupta A, Banu M, Lissanu Y, Shaffer S, Tawbi H, Li J, Gule-Monroe MK, Alvarez-Breckenridge CA, Huse JT, Murphy MB, Yin F, Lang FF, Parkes EE, Weinberg JS, Akdemir KC. Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases. medRxiv, 2025. e-Pub 2025. PMID: . PMCID: .
Citron F, Ho IL, Balestrieri C, Liu Z, Yen EN, Cecchetto L, Perelli L, Zhang L, Castillo Montanez LA, Blazanin N, Dyke CA, Shah R, Attanasio S, Srinivasan S, Chen KC, Chen Z, Scognamiglio I, Pham N, Khan H, Jiang S, Pan J, Vanderkruk B, Leung C, Mattohti M, Rai K, Chu Y, Wang L, Gao S, Deem AK, Carugo A, Wang H, Yao W, Tonon G, Xiong Y, Lorenzi PL, Bonini C, Zal A, Hoffman B, Giuliani V, Heffernan T, Jeter CR, Lissanu Y, Genovese G, Di Pilato M, Viale A, Draetta GF. WRAD core perturbation impairs DNA replication fidelity promoting immunoediting in pancreatic cancer. bioRxiv, 2025. e-Pub 2025. PMID: . PMC: .
Kotagiri S, Wang Y, Han Y, Liang X, Blazanin N, Nguyen PK, Jiang Y, Lissanu Y. Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors. bioRxiv, 2024. e-Pub 2024. PMID:. PMCID:.
Kotagiri, S, Blazanin, N, Xi, Y, Han, Y, Qudratullah, M, Liang, X, Wang, Y, Pandey, PR, Mazhar, H, Lam, TA, Singh, A, Wang, J, Lissanu, Y. Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer. Cell Chemical Biology 31(12):2069-2084.e9, 2024. e-Pub 2024. PMID: . PMCID: PMC11663135 (available on 2025-12-19).
Blazanin N, Liang X, Mahmud I, Kim E, Martinez S, Tan L, Chan W, Anvar NE, Ha MJ, Qudratullah M, Minelli R, Peoples M, Lorenzi P, Hart T, Lissanu Y. Therapeutic modulation of ROCK overcomes metabolic adaptation of cancer cells to OXPHOS inhibition and drives synergistic anti-tumor activity. bioRxiv, 2024. e-Pub 2024. PMID: . PMCID: .
Wang Y, Meraz IM, Qudratullah M, Kotagiri S, Han Y, Xi Y, Wang J, Lissanu Y. SMARCA4 mutation induces tumor cell-intrinsic defects in enhancer landscape and resistance to immunotherapy. bioRxiv, 2024. e-Pub 2024. PMID: . PMCID: .
Cai L, Gao Y, DeBerardinis RJ, Acquaah-Mensah G, Aidinis V, Beane JE, Biswal S, Chen T, Concepcion-Crisol CP, Gr¨¹ner BM, Jia D, Jones R, Kurie JM, Lee MG, Lindahl P, Lissanu Y, Lorz Lopez MC, Martinelli R, Mazur PK, Mazzilli SA, Mii S, Moll H, Moorehead R, Morrisey EE, Ng SR, Oser MG, Pandiri AR, Powell CA, Ramadori G, Santos Lafuente M, Snyder E, Sotillo R, Su KY, Taki T, Taparra K, Xia Y, van Veen E, Winslow MM, Xiao G, Rudin CM, Oliver TG, Xie Y, Minna JD. A Lung Cancer Mouse Model Database. bioRxiv, 2024. e-Pub 2024. PMID: . PMCID: .
Meraz IM, Majidi M, Fang B, Meng F, Gao L, Shao R, Song R, Li F, Lissanu Y, Chen H, Ha MJ, Wang Q, Wang J, Shpall E, Jung SY, Haderk F, Gui P, Riess JW, Olivas V, Bivona TG, Roth JA. 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. Commun Biol 6(1):509, 2023. e-Pub 2023. PMID: . PMCID: .
Inoue A, Robinson FS, Minelli R, Tomihara H, Rizi BS, Rose JL, Kodama T, Srinivasan S, Harris AL, Zuniga AM, Mullinax RA, Ma X, Seth S, Daniele JR, Peoples MD, Loponte S, Akdemir KC, Khor TO, Feng N, Roszik J, Sobieski MM, Brunell D, Stephan C, Giuliani V, Deem AK, Shingu T, Deribe YL, Menter DG, Heffernan TP, Viale A, Bristow CA, Kopetz S, Draetta GF, Genovese G, Carugo A. Sequential administration of XPO1 and ATR inhibitors enhances therapeutic response in TP53-mutated colorectal cancer. Gastroenterology 161(1):196-210, 2021. e-Pub 2021. PMID: . PMCID: .
Tomihara H, Carbone F, Perelli L, Huang JK, Soeung M, Rose JL, Robinson FS, Lissanu Deribe Y, Feng N, Takeda M, Inoue A, Poggetto ED, Deem AK, Maitra A, Msaouel P, Tannir NM, Draetta GF, Viale A, Heffernan TP, Bristow CA, Carugo A, Genovese G. Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress. Cancer Res 81(2):332-343, 2021. e-Pub 2021. PMID: . PMCID: .
Akdemir KC, Le VT, Kim JM, Killcoyne S, King DA, Lin Y, Tian Y, Inoue A, Amin S, Robinson FS, Nimmakayalu M, Herrera RE, Lynn EJ, Chan K, Seth S, Klimczak LJ, Gerstung M, Gordenin DA, O¡¯Brien J, Li L, Deribe L, G Verhaak |R, Campbell PJ, Fitzgerald R, Morrison AJ, Dixon JR, Futreal P. Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure. Nature Genetics, 2020. e-Pub 2020. PMID: . PMCID: .
Chakravarti D, Hu B, Mao DX, Rashid DA, Li J, Li DJ, Liao DW, Whitley E, Dey DP, Hou P, LaBella K, Chang A, Wang DG, Spring D, Deng P, Zhao D, Liang X, Lan Z, Lin Y, Sarkar DS, Terranova C, Lissanu Deribe Y, Blutt S, Okhuysen DP, Zhang DJ, Vilar DE, Nielsen PO, Dupont A, Younes M, Patel K, Shroyer N, Rai DK, Estes M, Wang Y, Bertuch A. Telomere dysfunction activates YAP1 to drive tissue inflammation. Nature Communications, 2020. e-Pub 2020. PMID: . PMCID: .
Lissanu Deribe Y, Sun Y, Terranova C, Khan F, Martinez-Ledesma J, Gay J, Gao G, Mullinax RA, Khor T, Feng N, Lin YH, Wu CC, Reyes C, Peng Q, Robinson F, Inoue A, Kochat V, Liu CG, Asara JM, Moran C, Muller F, Wang J, Fang B, Papadimitrakopoulou V, Wistuba II, Rai K, Marszalek J, Futreal PA. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat Med 24(7):1047-1057, 7/2018. e-Pub 6/2018. PMID: . PMCID: .
Lissanu Deribe Y, Shi Y, Rai K, Nezi L, Amin SB, Wu CC, Akdemir KC, Mahdavi M, Peng Q, Chang QE, Hornigold K, Arold ST, Welch HC, Garraway LA, Chin L. Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma. Proc Natl Acad Sci U S A 113(9):E1296-305, 3/2016. e-Pub 2/2016. PMID: . PMCID: .
Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, Wagle N, Sucker A, Sougnez C, Onofrio R, Ambrogio L, Auclair D, Fennell T, Carter SL, Drier Y, Stojanov P, Singer MA, Voet D, Jing R, Saksena G, Barretina J, Ramos AH, Pugh TJ, Stransky N, Parkin M, Winckler W, Mahan S, Ardlie K, Baldwin J, Wargo J, Schadendorf D, Meyerson M, Gabriel SB, Golub TR, Wagner SN, Lander ES, Getz G, Chin L, Garraway LA. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485(7399):502-6, 5/2012. e-Pub 5/2012. PMID: . PMCID: .
Ikeda F, Deribe YL, Sk?nland SS, Stieglitz B, Grabbe C, Franz-Wachtel M, van Wijk SJ, Goswami P, Nagy V, Terzic J, Tokunaga F, Androulidaki A, Nakagawa T, Pasparakis M, Iwai K, Sundberg JP, Schaefer L, Rittinger K, Macek B, Dikic I. SHARPIN forms a linear ubiquitin ligase complex regulating NF-¦ÊB activity and apoptosis. Nature 471(7340):637-41, 3/2011. PMID: . PMCID: .
Patents
Compounds And Methods For Selective Proteolysis Of Glucocorticoid Receptors